GL Biochem (Shanghai) Ltd. was founded in 1998 by Dr. Xu Hongyan and Ms. Zhou Min, establishing what would become one of the world's largest peptide synthesis companies. Headquartered at 519 Ziyue Road in the prestigious Zizhu Hi-Tech Industrial Development Zone of Minhang District, Shanghai, GL Biochem has grown from a small laboratory operation into a global peptide manufacturing powerhouse with over 1,500 employees and more than 100,000 square meters of production and research space across 8 production bases and 3 dedicated R&D centers.
The company claims over 60% share of the global research peptide market and has filed more than 200 patents relating to peptide synthesis technology, process optimization, and novel delivery systems. GL Biochem maintains international offices in Bedford, Massachusetts (USA), Canada, and Melbourne, Australia, supporting their global customer base across pharmaceutical, biotechnology, and academic research sectors. Their client portfolio includes some of the world's largest pharmaceutical companies: Roche, Merck, Bayer, Sigma-Aldrich, and Bachem AG.
GL Biochem's certification portfolio is among the most comprehensive in the industry, encompassing ISO 9001:2015, ISO 14001, cGMP, Drug Production License from China's NMPA, FDA Drug Master File filings, Certificates of European Pharmacopoeia (CEP), ICH Q7 and Q11 compliance, EU GMP, and REACH registration. This extensive regulatory compliance portfolio makes GL Biochem one of the few Chinese peptide manufacturers with genuine pharmaceutical-grade credentials recognized by Western regulatory bodies.
Dr. Xu Hongyan and Ms. Zhou Min establish GL Biochem in Shanghai, focusing on custom peptide synthesis services.
First major quality certification achieved, establishing formal quality management systems.
Construction of first cGMP-compliant production facility. Drug Production License obtained from NMPA.
Bedford, MA office opens. FDA Drug Master File filings submitted. European CEP obtained.
Major supply agreements with Roche, Merck, and Bayer. Production capacity reaches multi-ton scale.
Surpasses 100 patents filed. R&D team expands to 200+ scientists. EU GMP certification achieved.
Claims 60%+ global research peptide market share. 200+ patents. 1,500+ employees across 8 production bases.
GL Biochem's manufacturing capabilities span the full spectrum of peptide production, from milligram-scale custom synthesis for academic research to multi-kilogram GMP production for pharmaceutical clients. Their 8 production bases house a comprehensive array of synthesis, purification, and analytical equipment.
GL Biochem holds one of the most comprehensive certification portfolios in the peptide industry. These certifications are issued by recognized international regulatory bodies and are subject to periodic audits and renewal.
Quality Management System international standard
Environmental Management System certification
Current Good Manufacturing Practice compliance
NMPA (National Medical Products Administration) approved
Drug Master Files filed with US FDA
Certificate of European Pharmacopoeia suitability
API GMP & Development/Manufacture guidelines
European Union Good Manufacturing Practice
EU Registration, Evaluation, Authorization of Chemicals
GL Biochem's catalog spans 33 product categories with 1,817 individual catalog products. Their offerings range from research-grade peptides and amino acid derivatives to pharmaceutical-grade APIs and custom synthesis services.
Comprehensive catalog including GLP-1 agonists, GH secretagogues, and specialty peptides
Pharmaceutical-grade Active Pharmaceutical Ingredients for drug manufacturing
Protected amino acids, coupling reagents, and building blocks for peptide synthesis
Bespoke peptide synthesis from mg to multi-kg scale with full GMP documentation
Acetyl Hexapeptide-3, Palmitoyl Pentapeptide-4, and other cosmetic-grade peptides
Certified reference standards for analytical method development and validation
GL Biochem's analytical capabilities are industrial-scale, with over 200 HPLC systems, 10 LC-MS instruments, and specialized equipment including 400 MHz NMR and automated peptide synthesizers.
Agilent & Waters analytical and preparative HPLC
Liquid chromatography-mass spectrometry for identity confirmation
Nuclear magnetic resonance for structural elucidation
High-throughput automated peptide synthesis platforms
Industrial-scale freeze-drying equipment for peptide formulation
LAL-based endotoxin detection systems (USP <85>)
Moisture content analysis for lyophilized products
Residual solvent analysis and volatile impurity detection
GL Biochem supplies some of the world's largest pharmaceutical and life science companies. These partnerships represent long-term supply agreements that require the highest standards of quality, consistency, and regulatory compliance.
Swiss multinational pharmaceutical company
Global pharmaceutical & chemical company
German multinational pharmaceutical corporation
Global life science & biochemical company
Swiss leader in peptide & oligonucleotide manufacturing
As a pharmaceutical-grade manufacturer, GL Biochem's quality systems exceed those of typical research compound vendors. Their quality infrastructure supports both research-grade and GMP-grade production with full regulatory documentation trails.
Recent test results from community-submitted samples verified by Finnrick Analytics.
| Product | Batch # | Purity (HPLC) | Identity (MS) | Finnrick Grade | Test Date |
|---|---|---|---|---|---|
| Semaglutide API 100mg | GLB-SM-20260215 | 99.5% | Confirmed | A+ | Feb 2026 |
| Tirzepatide API 50mg | GLB-TZ-20260210 | 99.3% | Confirmed | A+ | Feb 2026 |
| Liraglutide API 100mg | GLB-LR-20260208 | 99.4% | Confirmed | A+ | Feb 2026 |
| Exenatide API 50mg | GLB-EX-20260205 | 99.2% | Confirmed | A+ | Feb 2026 |
| GLP-1 (7-36) amide 10mg | GLB-GLP1-20260118 | 99.1% | Confirmed | A | Jan 2026 |
| Oxytocin API 25mg | GLB-OXY-20260115 | 99.6% | Confirmed | A+ | Jan 2026 |
| Leuprolide API 100mg | GLB-LEU-20260112 | 99.4% | Confirmed | A+ | Jan 2026 |
| Gonadorelin API 50mg | GLB-GON-20260108 | 99.3% | Confirmed | A+ | Jan 2026 |
| BPC-157 Research 5mg | GLB-BPC-20260105 | 98.9% | Confirmed | A | Jan 2026 |
| Fmoc-Ala-OH (building block) | GLB-FAA-20251220 | 99.8% | Confirmed | A+ | Dec 2025 |
| GHK-Cu 50mg | GLB-GHK-20251218 | 99.0% | Confirmed | A | Dec 2025 |
| Acetyl Hexapeptide-3 100mg | GLB-AHX-20251215 | 99.2% | Confirmed | A+ | Dec 2025 |
Have you purchased from GL Biochem (Shanghai) Ltd.? Share your experience to help the community. You must have a registered account with 30+ days age and 10+ posts to submit a review.
GL Biochem is primarily a pharmaceutical-grade peptide manufacturer that also serves the research community. They are a large company with 1,500+ employees, 8 production bases, and partnerships with Roche, Merck, and Bayer. They produce both GMP-grade APIs for the pharmaceutical industry and research-grade peptides for academic and independent researchers. This pharmaceutical background results in higher quality standards and more comprehensive documentation than typical research-only vendors.
Yes, but the process is more formal than with typical research peptide vendors. GL Biochem's catalog products are available for individual purchase, though some items have minimum order quantities. Custom synthesis is available at any scale but pricing for small quantities may be higher than dedicated research-grade vendors. The Bedford, MA office can facilitate orders for US-based researchers. For the best experience, contact their sales team directly for a quotation.
GL Biochem's 4.4/5 trust score reflects the fact that their pharmaceutical-oriented processes (longer lead times, formal quotation process, minimum quantities) can be friction points for individual researchers accustomed to the streamlined ordering of dedicated research peptide vendors. The product quality itself (averaging 99.3% purity on Finnrick testing) is actually the highest of any vendor tracked by CompoundTalk. The lower score reflects accessibility rather than quality concerns.
GL Biochem holds: ISO 9001:2015, ISO 14001, cGMP, Drug Production License from China's NMPA, FDA Drug Master File filings, Certificate of European Pharmacopoeia (CEP), ICH Q7 and Q11 compliance, EU GMP, and REACH registration. This is one of the most comprehensive regulatory compliance portfolios in the peptide industry and is a key differentiator from research-only vendors.
Yes. GL Biochem has supply agreements with multiple major pharmaceutical companies including Roche, Merck, Bayer, Sigma-Aldrich, and Bachem AG. These partnerships require meeting stringent pharmaceutical quality standards including regular facility audits, quality system reviews, and ongoing compliance with international GMP regulations.
GL Biochem operates over 200 HPLC systems (both analytical and preparative), 10 LC-MS instruments, a 400 MHz NMR spectrometer, and numerous automated peptide synthesizers across their 8 production bases and 3 R&D centers. This analytical capacity supports both their research catalog production and large-scale pharmaceutical manufacturing operations.
Yes. GL Biochem operates an office in Bedford, Massachusetts, USA. They also have offices in Canada and Melbourne, Australia. US-based institutional researchers and pharmaceutical clients can work directly with the Bedford office for procurement, regulatory documentation, and technical support.
Catalog products typically ship within 5-10 business days. Custom synthesis projects range from 2-6 weeks depending on sequence complexity, scale, and purity requirements. The quotation process itself may take 2-5 business days. For time-sensitive research, it is recommended to plan procurement in advance. Rush services are available at additional cost for catalog items.